Quotient and Ortho Clinical Diagnostics to Present Symposium on Role of Extended Phenotyping in Blood Matching at ISBT
(firmenpresse) - EYSINS, SWITZERLAND and RARITAN, NJ -- (Marketwired) -- 06/20/17 -- Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company, and Ortho Clinical Diagnostics ("Ortho"), a global leader of in vitro diagnostics, today announced they will jointly host a company-sponsored satellite symposium, "Improving Patient Care with Better-matched Blood," on Tuesday, June 20 from 12:00-1:30 p.m., during the 27th Regional Congress of the International Society of Blood Transfusion (ISBT). The ISBT Regional Congress takes place this week in Copenhagen, Denmark.
"The symposium will feature expert perspectives on the limitations of current immunohematology, or blood-matching, practices and potential changes that could dramatically influence future standards of care in transfusion medicine," said Heidi Casaletto, vice president of Transfusion Medicine at Ortho.
"Better matching of donor units to patients is imperative in reducing alloimmunization during transfusions. Alloimmunization poses a threat to patient safety as well as compatibility issues in subsequent transfusions, resulting in a significant economic impact on blood establishments and hospitals," added Paul Cowan, chairman and chief executive officer at Quotient.
Speakers include:
Dr. Jonathan Wallis, Newcastle Hospital, UK: "Antibodies and the Haematology Patient"
Dr. Jill Storry, Lund University, Sweden: "Strategies to Provide Phenotyped Blood from a Blood Centre"
Prof. David Roberts, John Radcliffe Hospital, University of Oxford, UK: "The Future of Blood Group Matching"
During the symposium, which will be moderated by Dr. Geoffrey David Poole (an external consultant for Ortho), speakers will address the role of extended phenotyping to better match donor units to patients, reducing the risk of alloimmunization. They will also share examples of patient matching and advanced donor identification initiatives they have implemented.
Quotient will also be exhibiting at the Congress (booth no. C3.418).
In January 2015, Quotient and Ortho an agreement to bring MosaiQ™, an innovative transfusion medicine diagnostic platform, to the market. The new technology promises to allow improved time to test results and more comprehensive matching of donor and patient blood, beyond what is available in current transfusion diagnostic instruments.
Quotient is a commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the provision of innovative tests within established markets. With an initial focus on blood grouping and donor disease screening (transfusion diagnostics), Quotient is developing its proprietary MosaiQ™ technology platform to disrupt and transform the $3.4 billion global transfusion diagnostics market. Quotient has over 30 years of experience developing, manufacturing and commercializing transfusion diagnostic products. The company''s operations are based in Switzerland, Scotland and the US. For more information, visit: .
Ortho Clinical Diagnostics is a global leader of in vitro diagnostics serving the clinical laboratory and immunohematology communities. Across hospitals, hospital networks, blood banks and labs in more than 120 countries, Ortho''s high-quality products and services enable health care professionals to make better-informed treatment decisions. For the immunohematology community, Ortho''s blood typing products help ensure every patient receives blood that is safe, the right type and the right unit. Ortho brings sophisticated testing technologies, automation, information management and interpretation tools to clinical laboratories around the world to help them run more efficiently and effectively and improve patient care. Ortho''s purpose is to improve and save lives with diagnostics, and it does that by reimagining what''s possible. This is what has defined Ortho for more than 75 years, and it''s what drives Ortho forward. For more information, visit .
Nicole Barraud-Estoppey
Quotient Ltd
+41 79 550 64 75
Renee Giello
Ortho Clinical Diagnostics
908-704-3678
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 19.06.2017 - 22:00 Uhr
Sprache: Deutsch
News-ID 1509880
Anzahl Zeichen: 2869
contact information:
Contact person:
Town:
EYSINS, SWITZERLAND and RARITAN, NJ
Phone:
Kategorie:
Hospitals, Facilities and Providers
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 554 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Quotient and Ortho Clinical Diagnostics to Present Symposium on Role of Extended Phenotyping in Blood Matching at ISBT
"
steht unter der journalistisch-redaktionellen Verantwortung von
Quotient Limited; Ortho Clinical Diagnostics (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
